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re You Targeting
on–High-Density
ipoprotein Cholesterol?*
ennifer G. Robinson, MD, MPH
owa City, Iowa
on–high-density lipoprotein cholesterol (HDL-C) was
efined as the second lipid target of therapy in the 2001
ational Cholesterol Education Program-Adult Treatment
anel III guidelines (1), yet is not yet widely used in clinical
ractice. At no additional cost, non–HDL-C measures all
therogenic apolipoprotein B–containing lipoproteins, in-
luding low-density lipoprotein cholesterol (LDL-C), very
ow-density lipoprotein cholesterol, and to a lesser extent,
ntermediate-density lipoprotein cholesterol, lipoprotein (a),
hylomicrons, and chylomicron remnants (Fig. 1) (2). Not
urprisingly, non–HDL-C predicts cardiovascular risk bet-
er than LDL-C alone. Non–HDL-C is simply calculated
y subtracting HDL-C from total cholesterol. When trig-
ycerides are 200 to 500 mg/dl, non–HDL-C is 30 mg/dl
igher than LDL-C due to elevated levels of triglyceride-
ich lipoproteins. For this reason, the National Cholesterol
ducation Program Adult Treatment Panel III set the goal
or non–HDL-C 30 mg/dl higher than the LDL-C goal (1).
See page 35
In this issue of the Journal, the study by Arsenault et al.
3) is a welcome addition to the growing body of support for
on–HDL-C as a target of therapy and extends the contri-
ution of non–HDL-C to cardiovascular risk to even lower
DL-C levels. This study evaluated 11-year follow-up data
rom the EPIC (European Prospective Investigation Into
ancer and Nutrition)-Norfolk study, which included a
rimary prevention population of over 21,000 men and
omen age 45 to 79 years at baseline. A non–HDL-C 30
g/dl higher than LDL-C was found to predict increased
oronary heart disease (CHD) risk compared with non–
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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laxoSmithKline, Hoffman La Roche, Merck, and Merck/Schering-Plough; and
as also served as a consultant on the advisory board for AstraZeneca.DL-C 30 mg/dl higher than the LDL-C level. Excess
isk attributable to non–HDL-C occurred across increasing
DL-C categories for both men and women. Even when
DL-C was 100 mg/dl, those with non–HDL-C 130
g/dl had excess CHD risk 1.8-fold higher than when
on–HDL-C was 130 mg/dl. Notably, this analysis was
ot confined to those with triglyceride levels 200 to 499
g/dl, as recommended by the National Cholesterol Edu-
ation Program Adult Treatment Panel III (1).
The EPIC-Norfolk analysis also found that at each
DL-C level, those with nonfasting triglycerides 150
g/dl were at greater CHD risk than those with lower
riglyceride levels, which was most notable when LDL-C
as 100 mg/dl (hazard ratio: 1.6 [95% confidence inter-
als: 1.02 to 2.59]). None of the analyses were adjusted for
he presence of diabetes, insulin resistance, or HDL-C level.
herefore, conclusions regarding the strength of the asso-
iation between hypertriglyceridemia and CHD risk in this
tudy may be limited, especially as previous analyses of the
PIC-Norfolk and other populations found that the rela-
ionship between triglycerides and CHD risk was substan-
ially attenuated after adjustment for these factors (4). On
he other hand, more pertinent to statin-treated patients,
he PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
valuation and Infection Therapy–Thrombolysis In Myo-
ardial Infarction 22) study found those with fasting triglyc-
rides 150 mg/dl were still at increased CHD risk after
ore complete adjustment for confounders (5). The
ROVE IT–TIMI 22 study further found excess risk due to
levated triglycerides persisted even when on-treatment
DL-C levels are 70 mg/dl.
The EPIC-Norfolk study is consistent with other studies
n finding that nonfasting triglycerides have recently been
hown to be better predictors of cardiovascular risk than
asting levels (6). However, lack of a standardized protocol
or quantitation of post-prandial hypertriglyceridemia limits
ts clinical application. In contrast, post-prandial chylomi-
ronemia minimally influences the relationship between
on–HDL-C levels and CHD risk (Fig. 1) and is another
trength of non–HDL-C as a target of therapy (5).
What are the implications for clinical practice? We have
hown that non–HDL-C lowering predicts CHD risk
eduction in a 1:1 relationship in trials of drugs used as
onotherapy and that non–HDL-C was twice as good as
DL-C for predicting risk reduction (7). Individual-level
nalysis of the TNT (Treating to New Targets) and
DEAL (Incremental Decrease in End Points Through
ggressive Lipid Lowering) trials comparing atorvastatin
0 mg to pravastatin 40 mg or simvastatin 20 to 40 mg,
espectively, also confirmed that non–HDL-C was a supe-
ior risk predictor to LDL-C (8). Clearly, non–HDL-C
hould be routinely used as a target of therapy to reduce
ardiovascular risk. Whether non–HDL-C should replace
DL-C as the sole target of therapy will need to be
ddressed in future guidelines.
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December 29, 2009/January 5, 2010:42–4 Non-HDL CholesterolIn contrast to the clear relationship between non–
DL-C lowering and cardiovascular risk reduction, drug
herapy to lower triglycerides per se has not yet been shown
o provide incremental risk reduction beyond that obtained
rom LDL-C or non–HDL-C–directed therapy (9). Re-
ults from the ACCORD (Action to Control Cardiovascu-
ar Risk in Diabetes) trial will be reported soon and should
elp to clarify whether the addition of fenofibrate to
imvastatin therapy will provide incremental benefit beyond
hat expected from the degree of non–HDL-C lowering
10). The ongoing AIM HIGH: Niacin Plus Statin to
revent Vascular Events trial is evaluating whether lowering
riglycerides and raising HDL-C with extended-release
iacin will provide incremental benefit over simvastatin
herapy when both treatment groups achieve similar
DL-C levels (11). In the meantime, in light of a recent
eta-analysis showing that changes in triglycerides (or
DL-C) from statins, niacin, or fibrates failed to predict
HD risk (9), there is no compelling reason to specifically
arget therapy to triglycerides or HDL-C. This should be
ept in mind when evaluating recent marketing campaigns
dentifying triglyceride and HDL-C abnormalities as tar-
ets for reducing “residual risk” in statin-treated patients.
riglyceride and HDL-C abnormalities are certainly mark-
rs of obesity, insulin resistance, and physical inactivity, and
ifestyle modification may be the most appropriate risk
eduction strategy (12). Smoking, hypertension, and the
hrombotic state are proven targets of evidence-based ther-
Chylomicrons  VLDL  IDL   LDL   Lp(a)   HDL 
LDL-C 
Atherogenic Lipoproteins 
Non-HDL-C 
Plasma lipoproteins 
Atherogenic Triglyceride-
rich Lipoproteins 
              Apo B48                         Apo B100     Apo B100   Apo B100        Apo B100          Apo A-I     
 & remnants 
Figure 1 Targets of Therapy
Low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein
cholesterol (non–HDL-C) are recommended as the first and second targets of
lipid therapy. Non–HDL-C includes LDL-C and atherogenic triglyceride-rich
lipoproteins. Very low-density lipoproteins (VLDLs) are often elevated when tri-
glyceride levels exceed 200 mg/dl. Estimated LDL-C calculated by the Friede-
wald formula also includes intermediate-density lipoproteins (IDLs) and
lipoprotein (a) [Lp(a)]. Plasma triglyceride level reflects the triglyceride content
of all lipoproteins. Clinical assays measure both apolipoprotein B (Apo B) 100
and Apo B48 particles (Barter P, Ballantyne C, Carmena R, et al. Apo B versus
cholesterol in estimating cardiovascular risk and in guiding therapy: report of
the thirty-person/ten-country panel. J Intern Med 2006;259:247–58). Each
LDL-C, IDL cholesterol, VLDL cholesterol, and Lp(a) particle contains 1 Apo
B100 molecule, and each chylomicron or chylomicron remnant contains 1 Apo
B48 molecule. Chylomicrons and remnants are rapidly metabolized and contrib-
ute little to total Apo B levels. Adapted in part, with permission, from Miller et
al. (2).py. Indeed, we have suggested that such therapies mayesult in greater reduction in risk than efforts to drive
DL-C to very low levels, given the log linear relationship
etween LDL-C and cardiovascular risk (13).
Some have advocated apolipoprotein B as an additional
arget or replacement for LDL-C and non–HDL-C levels,
specially in those with diabetes (14). Given the added
xpense, lack of availability, and in some cases measurement
uality issues of apolipoprotein B, non-HDL has numerous
dvantages over apolipoprotein B and other measures of
article size and number (15). Because statins are first-line
herapy for cardiovascular risk reduction, it is important to
ote that apolipoprotein B, although superior to LDL-C,
rovides virtually no additional information over that ob-
ained from non–HDL-C in statin-treated individuals
8,16). Efforts are underway to have non–HDL-C reported
n all routine lipid panels (14).
Given the superiority of non–HDL-C to other lipid
easures for risk prediction, and the proven benefit of
on–HDL-C–lowering therapies, future guidelines will
o doubt continue to emphasize the importance of
on–HDL-C for guiding cardiovascular prevention strat-
gies. Ultimately, it may be desirable to move toward
on-HDL as the primary target of therapy once non–
DL-C has been routinely incorporated into clinical
ractice.
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irector, Lipid Research Clinic, University of Iowa, 200 Hawkins
rive SE 223 GH, Iowa City, Iowa 52242. E-mail: jennifer-g-
obinson@uiowa.edu.
EFERENCES
1. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Executive summary of the third report of the
National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, And Treatment of High Blood Cholesterol In
Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
2. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and
predictive value of non–high-density lipoprotein cholesterol for coro-
nary heart disease. Am J Cardiol 2008;101:1003–8.
3. Arsenault BJ, Rana JS, Stroes ESG, et al. Beyond low-density
lipoprotein cholesterol: respective contributions of non– high-
density lipoprotein cholesterol levels, triglycerides, and the total
cholesterol/high-density lipoprotein cholesterol ratio to coronary
heart disease risk in apparently healthy men and women. J Am Coll
Cardiol 2010;55:35– 41.
4. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of
coronary heart disease: 10,158 incident cases among 262,525 partici-
pants in 29 Western prospective studies. Circulation 2007;115:450–8.
5. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E.
Impact of triglyceride levels beyond low-density lipoprotein cholesterol
after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am
Coll Cardiol 2008;51:724–30.
6. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting
compared with nonfasting triglycerides and risk of cardiovascular
events in women. JAMA 2007;298:309–16.
7. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of
the relationship between non– high-density lipoprotein cholesterol
reduction and coronary heart disease risk. J Am Coll Cardiol
2009;53:316 –22.
11
1
1
1
1
1
K
l
44 Robinson JACC Vol. 55, No. 1, 2010
Non-HDL Cholesterol December 29, 2009/January 5, 2010:42–48. Kastelein JJP, van der Stieg W, Holme I, et al. Lipids, apolipoproteins,
and their ratios in relation to cardiovascular events with statin
treatment. Circulation 2008;117:3002–9.
9. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between
change in high density lipoprotein cholesterol and cardiovascular
disease morbidity and mortality: systematic review and meta-
regression analysis. BMJ 2009;338:b92.
0. Ginsberg HN, Bonds DE, Lovato LC, et al., on behalf of the
ACCORD Study Group. Evolution of the lipid trial protocol of the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Am J Cardiol 2007;99:S56–67.
1. AIM-HIGH: Niacin plus statin to prevent vascular events
(NCT00120289). National Heart Lung and Blood Institute, 2006.
Available at: http://www.clinicaltrials.gov/show/NCT00120289.
Accessed November 21, 2006.
2. Mozaffarian D, Wilson PWF, Kannel WB. Beyond established and
novel risk factors: lifestyle risk factors for cardiovascular disease.
Circulation 2008;117:3031–8. l3. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol
lowering: the risk curve concept. Am J Cardiol 2006;98:1405–8.
4. Sniderman AD. The case against ApoB and the ApoB:ApoA-I ratio:
are they right? Future Lipidol 2008;3:257–64.
5. Blaha M, Blumenthal R, Brinton E, Jacobson T, on behalf of the
National Lipid Association Taskforce on Non-HDL Cholesterol. The
importance of non-HDL cholesterol reporting in lipid management.
J Clin Lipidol 2008;2:267–73.
6. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the
relationship between apolipoprotein B and low-density lipoprotein
cholesterol and non-high-density lipoprotein cholesterol targets in
high-risk patients: the MERCURY II (Measuring Effective Reduc-
tions in Cholesterol Using Rosuvastatin therapY II) trial. J Am Coll
Cardiol 2008;52:626–32.
ey Words: low-density lipoprotein cholesterol y non–high-density
ipoprotein cholesterol y triglycerides y total cholesterol/high-density
ipoprotein cholesterol ratio y coronary heart disease risk.
